Early-stage financing for Canadian startup developing ultrafast laser treatment of several eye diseases.

A company that’s working on a revolutionary solution for patients suffering from major eye diseases took home the top prize in the Edmonton third of Startup TNT’s Investment Summit IV.

PulseMedica has raised an oversubscribed $2.6-million seed round, which it largely plans to use to run its first clinical trial beginning in June. The University of Alberta spinoff company is working on a new way to treat patients with major eye diseases.

In September 2021's edition of Radio Active, CBC News' Liam Harop spoke with PulseMedica's co-founder and CEO, Nir Katchinskiy about the potential impact of the company's innovative laser treatment device.

The OIS podcast features leaders and drivers of ophthalmic innovation from around the world. In January 2022, PulseMedica’s CEO Nir Katchinskiy and Advisor Lahav Gil joined Dr. Ehsan Sadri MD FACS on the Ophthalmology Innovation Source (OIS) podcast.

PulseMedica is making progress in its quest to provide a “revolutionary solution” for patients suffering from major eye diseases. The Edmonton company is developing technology that will treat afflictions such as age-related macular degeneration (AMD) with lasers instead of injections, to put it simply, though it goes much further than that.